Voyager Therapeutics, Inc. (VYGR)

USD 5.79

(-7.36%)

Market Cap (In USD)

316.28 Million

Revenue (In USD)

250 Million

Net Income (In USD)

132.33 Million

Avg. Volume

457.6 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.19-11.72
PE
-
EPS
-
Beta Value
0.889
ISIN
US92915B1061
CUSIP
92915B106
CIK
1640266
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Employee Count
-
Website
https://www.voyagertherapeutics.com
Ipo Date
2015-11-11
Details
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.